Abiopharma

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Avient To Hold Fourth Quarter 2025 Conference Call

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

GSK plc (GLAXF) Files Form 6-K

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Merck to Complete Acquisition of Cidara Therapeutics

(99% Neutral) COMPASS PATHWAYS PLC (CMPS) Announces Regulatory Update

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3